Stoke Therapeutics, Inc.
HealthcareNASDAQ:STOK · NASDAQ Global Select
+$0.46 today
Vol 0.46M · Avg 0.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-2.0%
avg 20.6%
ROIC
-5.7%
avg -62.2%
ROA
-1.6%
avg -47.4%
Analysis
ROA is currently the strongest return metric at -1.6% versus its period average of -47.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ian F. Smith | Chief Executive Officer & Director | $1.41M | — | 60 | $17,786.00 | 0.03% |
Jason Hoitt | Chief Patient Officer | $815,418.00 | — | 48 | $10,445.00 | 0.02% |
Thomas Edward Leggett | Chief Financial Officer | $804,024.00 | — | 49 | $17,786.00 | 0.03% |
Edward Kaye | Advisor & Director | $736,384.00 | — | 77 | $17,786.00 | 0.03% |
Barry S. Ticho FACC | Chief Medical Officer | $726,501.00 | — | 65 | $34,826.00 | 0.06% |
Adrian R. Krainer | Co-Founder & Independent Director | $45,000.00 | — | 67 | $17,786.00 | 0.03% |
Doug Snow | Director of Communications & Investor Relations | — | — | — | — | — |
Jonathan Allan | Corporate Secretary & General Counsel | — | — | 36 | $19,543.00 | 0.03% |
Dawn Kalmar | Chief of Corporate Affairs & Strategic Partnerships | — | — | 49 | — | — |
Isabel Aznarez | Co-Founder, Head of Research & Senior Vice President | — | — | 53 | — | — |
Sara Den Besten | Chief People Officer | — | — | — | — | — |
Susan Willson | Vice President of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
85
$12.20M
Net Sentiment
$12.20M
Net selling
Most Active
Ticho Barry
26 transactions
1–10 of 85
Analysis
Insiders reported 0 buys worth $0.00 and 85 sells worth $12.20M over the last 12 months. That adds up to net selling of $12.20M. Ticho Barry was the most active insider with 26 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.83B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Novavax, Inc.
NASDAQ:NVAX
$1.46B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
Upstream Bio, Inc.
UPB
$331.96M
Who manages STOK?
Stoke Therapeutics, Inc. (STOK) lists 12 active executives. The top listed executive is Doug Snow, Director of Communications & Investor Relations.
Are STOK insiders buying or selling?
Recent insider activity shows net selling of $480,350.21.
Explore More
Continue the stock analysis
Jump to another research area for this company.